Searched for
XP23829
New psoriasis drug study yields positive results: Dr Reddy'sAccording to a press release from the city-based drug-maker, the detailed safety and efficacy data from the study would be presented in fut...- Dr Reddy’s Laboratories inks US licensing pact with XenoPortDr Reddy’s Laboratories will pay an upfront fee of $50 million to XenoPort and up to $440 million on achievement of certain milestones.
- Dr Reddy's signs US licensing agreement with XenoPortDr Reddy's Laboratories said it is planning to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis.
- Load More